Global Cancer Kinase Inhibitors Market & Pipeline Insight The recent years have witnessed the emergence of kinase inhibitors, which have the potential
to offer less toxic and more efficient therapeutic alternatives for patients. Over the past two decades, the researchers have increased their learning about the functioning of these
inhibitors, which has led to the achievement of significant milestones of development during
this period. The use of inhibitors for treating cancer is gradually increasing. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body’s acceptance of inhibitors so as to develop more efficient drugs.
The field of cancer is growing mainly because of the globally aging population, increasing
rates of obesity and rising smoking rates across all regions. This opens the door of opportunities for the drug makers globally because the kinase inhibitors is highly competitive
and is currently in growing stages, thus offering significant areas of unmet medical need. The future years are likely to witness significantly increased levels of activity in the development of these drugs.
Additionally, with the industry undergoing the period of “patent cliff�, the pharma companies are rapidly working towards filling up their exhausting pipelines with alternative and
innovative drugs. Kinase inhibitors fit these spaces most appropriately, which is likely to drive future growth and improve the survival rates of cancer patients.
A significant amount of research is being carried out currently to improve the level of potency of the already developed kinase inhibitors. Consequently, a relatively new approach has been
indentified in which the precision of targeting molecules would be combined with the proved killing power of radiation or cytotoxic chemotherapy which is referred to as payload to precise molecular carriers. However, still a lot of work needs to be done in this arena.
It is expected that during the next decade, with the discovery and introduction of new tumorspecific proteins, newer kinase inhibitor drugs targets would be successfully identified for
regulating tumor cell growth. Additionally, the innovations and dynamics in inhibitors would
also allow for more efficient cytotoxic kinase inhibitor drug targeting or lead to more efficient activation of host effector mechanisms which tend to lead to better therapeutic targets.
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 1
Global Cancer Kinase Inhibitors Market & Pipeline Insight “Global Cancer Kinase Inhibitors Market & Pipeline Insight” Report Highlight: • • • • • • •
Classification & Mechanism of Kinase Inhibitors
Cancer Kinase Inhibitors Therapy Market Overview
Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country
Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country
Patent Analysis & Orphan Designation of Kinase Inhibitors
Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs
Marketed Cancer Kinase Inhibitors: 35 Drugs
For Report Sample Contact: neeraj@kuickresearch.com
Table of Contents 1. Introduction to Kinase Inhibitors 1.1 Cancer Growth Blockers 1.2 Types of Cancer Growth Blockers 1.3 Tyrosine Kinase Inhibitors 2. Kinase Inhibitors Classification 2.1 Type I Kinase Inhibitors 2.2 Type II Kinase Inhibitors 2.3 Type III Kinase Inhibitors 2.4 Type IV Kinase Inhibitors or Substrate Directed Inhibitors 2.5 Covalent Inhibitors For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 2
Global Cancer Kinase Inhibitors Market & Pipeline Insight 3. Mechanisms of Kinase Inhibitors 3.1 Biochemical Mechanism of Action of Tyrosine Kinase 3.2 Oncogenic Activation of Tyrosine Kinase 3.2.1 Activation by Mutation 3.2.2 BCR-ABL and Human Leukemia 3.2.3 TEL-ABL and Human Leukemia 3.2.4 Autocrine-Paracrine Loops 3.2.5 EGFR in Autocrine Paracrine Loops 3.2.6 PDGFR in Autocrine Paracrine Loop 3.2.7 Insulin like Growth Factor Receptors in Autocrine Growth Loop 3.3 Tyrosine Kinases as Targets for Anticancer Agents 4. Need for Cancer Kinase Inhibitor Therapy 5. Cancer Kinase Inhibitors Therapy Market Overview 5.1 Current Market Scenario 5.2 Cancer Kinase Inhibitors Pipeline Overview 6. Cancer Kinase Inhibitors Therapy Market Dynamics 6.1 Favorable Parameters 6.2 Growth Restraints 7. Cancer Kinase Inhibitors Therapy Market Future Outlook 8. Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country 8.1 Phase: Unknown 8.2 Phase: Research 8.3 Phase: Preclinical 8.4 Phase: Clinical For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 3
Global Cancer Kinase Inhibitors Market & Pipeline Insight 8.5 Phase-I 8.6 Phase-I/II 8.7 Phase-II 8.8 Phase-II/III 8.9 Phase-III 8.10 Preregistration 8.11 Registered 9. Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country 10. Suspended & Discontinued in Cancer Kinase Inhibitors Therapy Pipeline 10.1 No Development Reported 10.2 Discontinued 10.3 Suspended 11. Competitive Landscape 11.1 Amgen 11.2 AstraZeneca 11.3 AVEO Pharmaceuticals 11.4 Bayer HealthCare Pharmaceuticals 11.5 Boehringer Ingelheim 11.6 Deciphera Pharmaceuticals 11.7 Genentech 11.8 GlaxoSmithKline 11.9 Incyte Corporation 11.10 Novartis 11.11 Pfizer For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 4
Global Cancer Kinase Inhibitors Market & Pipeline Insight 11.12 Takeda
List of Figures Figure 2-1: Kinase Inhibitors Classification Figure 3-1: Mechanisms of Constitutive Activation of Kinase Inhibitors Figure 5-1: Global Market for Kinase Inhibitors (US$ Billion), 2013-2020 Figure 5-2: Global Market for Cancer Kinase Inhibitors (US$ Billion), 2013-2020 Figure 5-3: Regional Break-Up for Kinase Inhibitors Market (%), 2013 & 2020 Figure 5-4: Cancer Kinase Inhibitors Pipeline by Phase (%), 2014 Figure 5-5: Cancer Kinase Inhibitors Pipeline by Phase (%), 2014 Figure 5-6: No Development Reported in Cancer Kinase Inhibitors Pipeline by Phase (%), 2014 Figure 5-7: No Development Reported in Cancer Kinase Inhibitors Pipeline by Phase (Number), 2014 Figure 5-8: Discontinued Cancer Kinase Inhibitors Pipeline by Phase (%), 2014 Figure 5-9: Discontinued Cancer Kinase Inhibitors Pipeline by Phase (Number), 2014 Figure 5-10: Suspended Cancer Kinase Inhibitors Pipeline by Phase (%), 2014 Figure 5-11: Suspended Cancer Kinase Inhibitors Pipeline by Phase (Number), 2014 Table 1-1: Drugs Targeting Kinase Inhibitors Table 2-1: Comparison Between Different Types of Kinase Inhibitors
For Report Sample Contact: neeraj@kuickresearch.com
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 5